Clinical Translational Catalyst

From Clinical Trial to Commercialisation:
Shared Risk, Shared Success

Catalysing clinical translation to bring innovative, life-changing therapies and technologies to patients, the Clinical Translational Catalyst (CTC) is a highly specialized platform to provide all-round support to biomedical companies in pre-clinical and early clinical stage.

Under this programme, Financial Support will be provided to biomedical companies of HKSTP with highly promising pre-clinical/ clinical projects. In addition, a Professional Network of key stakeholders are engaged by CTC team to work together with your product development towards attaining regulatory approvals, conducting clinical trials and achieving commercialisation. To transform Hong Kong as a leading clinical translational research hub within the region, an overarching Clinical Translational Consortium has been established.

Financial Support

Regulatory Affairs Funding Scheme*

Subsidise 50% of expenditure for pre-clinical/non-clinical activities for

• Therapeutics, up to HKD 4 million
• In Vitro Diagnostics/Medical Devices
  • Class II, up to HKD 0.5 million
  • De novo, up to HKD 1 million
  • Class III, up to HKD 2.5 million

Clinical Trial Funding Scheme*

Subsidise 50% of expenditure for clinical trials for Therapeutics, Medical Devices and In Vitro Diagnostics

• Therapeutics
  • Phase I, up to HKD 8 million
  • Phase II, up to HKD 10 million
  • Phase III, up to HKD 12 million (must include Hong Kong as one of the trial sites)
• In Vitro Diagnostics/Medical Devices clinical trials for registration, up to HKD 8 million

Eligibility

You are eligible to apply for this highly selective programme if:

• You are an existing HKSTP tenant**
• You have at least three full-time staff working at your HKSTP leased premises
• You will remain as HKSTP tenant for the project period funded by the scheme
• The project coordinator and project team are full-time employees of your company at HKSTP

* Funded pipeline will be subject to Benefit-Sharing Agreement

* * Companies which are not HKSTP tenants should first apply for tenancy (standard lease term is for three years)

Professional Network

Providing access to scientific, clinical, technical and regulatory experts, as well as commercial partners, our Professional Network Support is available for catalysing the translation of novel and breakthrough biomedical technologies from pre-clinical to clinical development stage.

Support available via the Professional Network

• Learn about the latest regulatory updates via webinars and workshops
• Connect with experts to understand the regulatory approval and clinical trial processes
• Establish your network of principal investigators, technical experts and commercial partners (e.g. CROs, CDMOs and CMOs)

ASK CTC! is a specialized HELPDESK designed to help biomedical companies to kick-start their translational journey towards regulatory submissions and clinical trials.

Partners In Our Professional Network

Clinical Translational Consortium

On behalf of the Hong Kong clinical research community, the Clinical Translational Consortium is established to provide strategic thought and SUPPORT policy development for strengthening the clinical translation research environment.

Vision

Establish Hong Kong as a leading clinical trial hub within the region.

Mission

Strengthen Hong Kong’s clinical trial environment by leveraging the combined strengths of Hong Kong and the rest of the Greater Bay Area.

Goals

• Provide strategic thoughts and implement ideas to strengthen local clinical research environment and enhance the competitiveness of Hong Kong as a clinical trial hub
• Build an information platform and provide the industry, academic, and public with compendious information about clinical trials in Hong Kong
• Promote Hong Kong as a clinical trial hub and attract national and overseas biomedical companies landing in Hong Kong

Our Consortium Members

Our Work

Hong Kong Science & Technology Parks Corporation supported Our Hong Kong Foundation in the release of the research report - “Developing Hong Kong into Asia’s Leading Clinical Innovation Hub”, on the 30 November 2023. Drawing upon insights from 250+ stakeholders, the report identifies clinical research as a strategic pillar of Hong Kong’s Innovation & Technology Development and advocates for the Government to strengthen its role in facilitating clinical research through a Clinical Research Institute, establish a primary review authority for drug registration and to build a comprehensive talent development strategy. The research report had been submitted to the Health Bureau, the Innovation, Technology and Industry Bureau and 2023 Policy Address Public Consultation.

Click to read the e-version of the research report